MiniMed Launches Abbott Instinct Sensors Across European Markets
MiniMed (MMED) has launched Abbott's Instinct continuous glucose monitoring sensors in European markets, expanding its diabetes technology reach and boosting user flexibility within its connected care ecosystem.
MiniMed (MMED) announced the launch of Abbott's Instinct continuous glucose monitoring (CGM) sensors across European markets, aiming to expand its diabetes technology portfolio and strengthen its connected care ecosystem.
The Product
Instinct sensors are CGM devices developed by Abbott Laboratories (ABT). They provide real-time glucose readings, helping diabetes patients manage their condition more effectively. The device features a compact design, ease of use, and a battery life of up to 14 days.
Availability and Pricing
The Instinct sensors will be available through MiniMed's network in several European countries starting July 2026. Official pricing has not been announced yet, but it is expected to be competitive with other CGM devices on the market.
Competition
Instinct sensors face competition from other CGM devices such as Dexcom G7 and Abbott's own Freestyle Libre 3. However, integration with MiniMed's connected care system could provide a competitive edge.
Potential Impact on the Company
This launch is expected to boost MiniMed's revenue in the diabetes segment and increase its market share in Europe. It also strengthens the partnership with Abbott, potentially leading to broader future collaboration.
Frequently Asked Questions
Found this useful? Share it